Log In
BCIQ
Print this Print this
 

Movantik, Naloxegol (Moventig) (formerly NKTR-118)

  Manage Alerts
Collapse Summary General Information
Company Nektar Therapeutics
DescriptionPEGylated form of naloxol, a peripheral mu opioid receptor (OPRM1; MOR) antagonist
Molecular Target Mu opioid receptor (MOR) (OPRM1)
Mechanism of ActionOpioid receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationConstipation
Indication DetailsTreat opioid-induced constipation (OIC)
Regulatory Designation U.S. - Undisclosed Review (Treat opioid-induced constipation (OIC));
EU - Standard Review (Treat opioid-induced constipation (OIC));
Canada - Standard Review (Treat opioid-induced constipation (OIC))
PartnerAstraZeneca plc;
Daiichi Sankyo Co. Ltd.;
Kyowa Hakko Kirin Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

3

$2,330.0M

$395.0M

$2,005.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today